Bioptimus Hits $76M Funding Milestone for AI-Based Biology Model

Bioptimus, an innovative AI company focused on biology, has successfully raised $76 million in funding. This includes a recent $41 million investment round, less than a year after its initial seed round.

This milestone will help the company push forward with its ambitious plans to create the world’s first universal AI foundation model for biology. The model is expected to revolutionize industries such as healthcare, biotech, and cosmetics by providing new ways to simulate complex biological systems.

The round was led by Cathay Innovation, a respected multistage venture capital firm. Other key participants included Sofinnova Partners, Bpifrance through its Large Venture Fund, Andera Partners, Hitachi Ventures, Boom Capital Ventures, Pomifer Capital, Sunrise, and angel investors Emmanuel Cassimatis and Thomas Wolf.

With such a strong group of investors behind it, Bioptimus is in a strong position to expand its innovative platform and further disrupt biological research and development across multiple sectors.

Bioptimus AI approach to unlock complex biological systems

Bioptimus is addressing a critical challenge in biology: the fragmented nature of research. Traditionally, biological research has focused on isolated components—like DNA, proteins, or cells—leading to a limited understanding of the bigger picture.

Even AI models often work within these isolated silos. Bioptimus is changing that. By integrating data across multiple scales (from molecules to entire organisms) and diverse modalities (such as imaging and genetics), their approach offers a more complete view of biology as it exists in the real world.

"What we are building is not just a technological breakthrough; it’s a transformative tool for understanding biology in its full complexity. By learning how biology works directly from raw data across scales, from molecules to whole organisms, our model will empower researchers in the pharmaceutical industry to simulate complex biology, predict disease outcomes and response to treatment, and design therapies with unprecedented precision. Beyond pharmaceuticals, this model will unlock limitless possibilities across many other industries, driving biological discoveries in ways we are only beginning to imagine. Essentially, it’s like the GPT of biology—but instead of generating text, we’re simulating biology."

Jean-Philippe Vert, co-founder and CEO of Bioptimus

Use of funds

The $76 million in new funding will enable Bioptimus to enhance its multi-modal AI platform, which integrates diverse biological data sources. This will improve the model’s ability to simulate biology on a scale never seen before. The funds will also help the company forge new partnerships with pharmaceutical and biotech companies, providing the necessary resources to refine and validate its models for real-world applications.

Bioptimus plans to use these funds to drive further innovation in the coming years. Its ultimate goal is to create a universal AI platform capable of simulating all aspects of biology. By continuing to break down barriers between different biological scales and data types, the company is positioning itself as a leader in biological research and development.

Bioptimus’s work could lead to breakthroughs in medical treatment, drug discovery, and other areas, all while fostering new opportunities for industries like cosmetics.

“Bioptimus is at the forefront of transforming biological research, leveraging cutting-edge AI to break down silos and unlock the full complexity of biology. By integrating data across multiple scales and modalities, Bioptimus is paving the way for groundbreaking innovations across industries, from pharmaceuticals to biotechnology and beyond. We are delighted to see that since our initial investment a year ago, Bioptimus has succeeded in structuring a world-class team, while achieving key milestones in its development, notably with the launch of its AI foundation model for pathology in July, the largest in the world.”

Jacky Abitbol, Managing Partner at Cathay Innovation

Company background

Bioptimus is a Paris-based AI company focused on transforming biological research through the power of artificial intelligence.

Their mission is to create the world’s first universal AI foundation model for biology, a tool that can simulate biology across a range of scales and data types.

Their innovative approach aims to bring more clarity and understanding to biological systems, empowering researchers in diverse fields like medicine and biotech.

The company was founded by Jean-Philippe Vert, an expert in AI and computational biology. Jean-Philippe serves as the company’s CEO and has been instrumental in leading its groundbreaking work in AI-driven biological models.

His leadership, combined with a world-class team of scientists, has allowed Bioptimus to rapidly develop and launch its first major AI model, H-Optimus-0, the largest AI foundation model for pathology, which has already outperformed others in independent benchmarks.

What sets Bioptimus apart is its holistic approach to biology. Instead of focusing on isolated biological elements, the company integrates data across multiple levels—molecules, cells, tissues, and organisms—offering a more complete view of biological systems.

This integration is key to unlocking new insights and driving innovation. Bioptimus is pushing the boundaries of what’s possible, enabling researchers to explore and simulate biology in ways that were previously unimaginable.

Investors

The support from top-tier investors reflects confidence in Bioptimus’s vision and its ability to transform the future of biological research. The funding will help Bioptimus continue its growth and refine its platform to deliver even more impactful results across industries.

This round was led by Cathay Innovation, a prominent global venture capital firm that partners with startups across North America, Europe, Asia, and Africa to accelerate innovation in diverse industries. Additional investors in this round include:

• Sofinnova Partners is a leading European venture capital firm specializing in life sciences. They invest in early-stage companies across the healthcare sector, including biotechnology, medical devices, and digital health.
• Bpifrance is the French public investment bank, supporting businesses at every stage of their development. They provide financing solutions, including loans, guarantees, and equity investments, to foster innovation and growth in the French economy.
• Andera Partners is a French private equity firm focusing on growth and buyout investments. They support companies in various sectors, including healthcare, technology, and consumer goods, aiming to accelerate their development and international expansion.
• Hitachi Ventures is the corporate venture capital arm of Hitachi Ltd., investing in startups that align with Hitachi's strategic interests. They focus on areas such as digital transformation, industrial IoT, and sustainable energy solutions.
• Boom Capital Ventures is a venture capital firm investing in early-stage technology companies. They focus on sectors like artificial intelligence, blockchain, and fintech, aiming to support innovative startups with high growth potential.
• Pomifer Capital is a private equity firm specializing in investments in the life sciences sector. They focus on companies developing innovative solutions in healthcare, biotechnology, and medical devices.
• Sunrise is a Swiss venture capital firm investing in early-stage technology companies. They focus on sectors such as software, digital media, and e-commerce, aiming to support startups with innovative business models.
• Emmanuel Cassimatis is an angel investor with a background in technology and entrepreneurship. He has invested in various startups, particularly in the tech and digital sectors, supporting their growth and development.
• Thomas Wolf is an angel investor and entrepreneur with experience in the technology industry. He has been involved in several startups, providing mentorship and funding to help them scale and succeed.

Source: BusinessWire